As an initial step of our investigation, to confirm the specificity of EPCAM-CL for EPCAM deletion-induced MSH2 deficient Lynch syndrome-associated CRC and to find clues of the clinicopathologic significance of EPCAM-PL in CRC, we evaluated EPCAM immunohistochemistry (IHC) in a large series of primary MSI-high CRCs. Here, MSH2 is linked to colorectal carcinoma.